Who is sponsoring NCT00396656?

NCT00396656 is sponsored by Novartis.

What condition does NCT00396656 study?

NCT00396656 studies Hypertension.

What drugs are being tested in NCT00396656?

Interventions: Atenolol, Hydrochlorothiazide (HCTZ)), Valsartan.

What is the status of NCT00396656?

NCT00396656 is currently COMPLETED.

Last reviewed 2011-05-05 · How we verify

A Randomized, Open-label, Multicenter, Cross-over Trial to Evaluate the Efficacy of a 20 Week Treatment of Valsartan 320 mg Versus Atenolol 100 mg in Combination With Hydrochlorothiazide on Microcirculation in Hypertensive Patients

NCT00396656 Phase 3 COMPLETED Results posted

This study evaluated the effect of valsartan on small vessel blood flow in patients with mild-to-moderate hypertension in direct comparison to atenolol and hydrochlorothiazide.

Details

Lead sponsor	Novartis
Phase	Phase 3
Status	COMPLETED
Enrolment	30
Start date	2005-12
Completion	2007-12

Conditions

Hypertension

Interventions

Atenolol
Hydrochlorothiazide (HCTZ))
Valsartan

Primary outcomes

Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected Sites — At end of each treatment period (Week 21 and Week 43)
10 µl of acetylcholine (ACH) at 3 concentrations (10-7, 10-8, 10-9 M) was injected intra-dermally at 3 sites on the forearms. NaCl was injected at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. Means for the 3 ACH and the 2 NaCl sites were calculated and compared. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.

Countries

Germany, Switzerland